Abstract:Platinum-based chemotherapeutics is the most common regimens for advanced NSCLC patients. However, it is difficult to identify platinum resistance in clinical treatment. Genetic factors are thought to represent important determinants of drug efficacy. In this study, we investigated whether single nucleotide polymorphisms (SNPs) in Xeroderma pigmentosum group G (XPG) and X-ray repair cross complementing group 1 (XRCC1) were associated with the tumor response in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy in Chinese population. Totally 82 patients with advanced NSCLC were routinely treated with cisplatin or carboplatin-based chemotherapy, and clinical response was evaluated after 2–3 cycles. And 3D (three dimensions) polyacrylamide gel-based DNA microarray method was used to evaluate the genotypes of XRCC1 194 Arg/Trp, XRCC1 399Arg/Gln, XPG 46His/His and XPG 1104His/Asp in DNA from peripheral lymphocytes. We found that there was a significantly increased chance of treatment response to platinum-based chemotherapy with the XRCC1 194Arg/Trp genotype (odds ratio 0.429; 95% CI 0.137–1.671; P=0.035). The polymorphism of XPG 46His/His was found to be associated with clinical response in NSCLC patients P=0.047, not detected between chemotherapy response and SNPs of XRCC1 399Arg/Gln or XPG 1104His/Asp (P=0.997 0.561, respectively). Our study showed that the polymorphic status of XRCC1 194Arg/Trp might be a predictive marker of treatment response for advanced NSCLC patients and those of XPG His46His was associated with susceptibility of chemotherapy. The 3D polyacrylamide gel-based DNA microarray method was accurate, high-throughput and inexpensive, especially suitable for a large scale of SNP genotyping in population.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Lack of Correlation Between ERCC1 (C8092A) Single Nucleotide Polymorphism and Efficacy/toxicity of Platinum Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Single Nucleotide Polymorphism in ERCC1 118C→T Predicts the Outcome of NSCLC Patients Receiving Platinum-Based Chemotherapy

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Relationship between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in advanced non-small cell lung cancer patients

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Relationship of ERCC1,XPD,and BRCA1 Polymorphisms with Efficacy of Platinum-Based Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum

Association Between Polymorphisms of Ercc1 and Xpd and Clinical Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy

Polymorphisms of ERCC1, XRCC1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

[Correlation of Genetic Polymorphisms in Nucleotide Excision Repair System to Sensitivity of Advanced Non-Small Cell Lung Cancer Patients to Platinum-Based Chemotherapy].

RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced NSCLC Patients Treated with Cisplatin-Based Chemotherapy

Assessment of XPD Lys751Gln and XRCC1 T–77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy